Showing 1771-1780 of 2652 results for "".
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- Schwind Celebrates 30 Years in Refractive Corneal Surgeryhttps://modernod.com/news/schwind-celebrates-30-years-in-refractive-corneal-surgery/2480804/In 2022, Schwind eye-tech-solutions is celebrating a milestone, as the company marks 30 years of driving solutions for refractive corneal surgery. During this period, Schwind has expanded its treatment options for eye surgeons and patients. Founded in 1958 and initially a successful one-stop supp
- Samsara Vision to Initiate a US PMA Supplemental Study of the SING IMT, a New-Generation Technology for AMDhttps://modernod.com/news/samsara-vision-to-initiate-a-us-pma-supplemental-study-of-the-sing-imt-a-new-generation-technology-for-amd/2480785/Samsara Vision announced FDA approval to initiate a US-based, PMA supplemental study to evaluate improvements in visual acuity and the safety of its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in people living with late-stage AMD. The CONCERTO trial w
- Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for Age-Related Macular Degenerationhttps://modernod.com/news/italian-patients-receive-samsara-visions-sing-imt-a-new-technology-for-age-related-macular-degeneration/2480658/Samsara Vision announced the first three successful clinical cases in Italy using its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) for people living with late-stage, age-related macular degeneration (AMD). The SING IMT was successfully implanted in patients
- Elios Reports 8-Year Results of its Excimer Laser Trabeculostomy Procedure Combined With Cataract Surgeryhttps://modernod.com/news/elios-reports-8-year-results-of-its-excimer-laser-trabeculostomy-procedure-combined-with-cataract-surgery/2480650/Elios Vision announced 8-year follow up results of its Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery. According to Elios, key finding of the study include: 161 eyes of 128 patients with glaucoma or ocular hypertension and cataract rec
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral Lumevoq Injections at 2-Year Follow-Up of REFLECT Phase 3 Trialhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-3-trial/2480513/GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit
- Hydrus Microstent Lowers Visual Field Loss by 47%, According to New 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/Ivantis, developer of the Hydrus Microstent, announced new data from its 5-year HORIZON t